Propanc Biopharma Receives Canadian Patent Allowance for Lead Cancer Drug PRP Propanc Biopharma has secured a key Canadian patent covering high-dose formulations of its lead asset, PRP, intended for treating recurring and metastatic cancers. This protection supports planned Phase 1 human trials. The patent adds to Propanc's broad portfolio, with similar grants in Europe, Japan, and Southeast Asia.123